Get the Stockscreener App
40.90
0.19%
-0.10
Spyre Therapeutics Inc stock is traded at $40.90, with a volume of 88,793.
It is down -0.19% in the last 24 hours and up +24.23% over the past month.
Spyre Therapeutics Inc is a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel disease (IBD) and rheumatic diseases. Spyre's pipeline includes extended half-life antibodies targeting α4β7, TL1A, and IL-23 in development as monotherapies and pair-wise combinations. It has a single reportable segment, which is the development of biopharmaceutical products for the treatment of patients with IBD and other immune-mediated disease.
See More
Previous Close:
$41.00
Open:
$40.34
24h Volume:
88,793
Relative Volume:
0.12
Market Cap:
$3.21B
Revenue:
$688.00K
Net Income/Loss:
$-170.19M
P/E Ratio:
-13.41
EPS:
-3.0495
Net Cash Flow:
$-154.68M
1W Performance:
-5.17%
1M Performance:
+24.23%
6M Performance:
+140.71%
1Y Performance:
+110.17%
1-Day Range:
$40.19
$41.50
1-Week Range:
$39.98
$43.80
52-Week Range:
$10.91
$45.76
Spyre Therapeutics Inc Stock (SYRE) Company Profile
Name
Spyre Therapeutics Inc
Sector
Industry
Phone
(617) 651-5940
Address
221 CRESCENT STREET, WALTHAM
Compare SYRE vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SYRE
Spyre Therapeutics Inc
|
40.90 | 3.22B | 688.00K | -170.19M | -154.68M | -3.0495 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.50 | 121.40B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
769.77 | 83.25B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
730.28 | 46.39B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
325.49 | 43.41B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
294.34 | 33.09B | 5.36B | 287.73M | 924.18M | 2.5229 |
Spyre Therapeutics Inc Stock (SYRE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-18-25 | Initiated | Mizuho | Outperform |
| Dec-17-25 | Initiated | Citigroup | Buy |
| Sep-26-25 | Initiated | Deutsche Bank | Buy |
| Apr-08-25 | Initiated | Leerink Partners | Outperform |
| Mar-18-25 | Initiated | Wolfe Research | Outperform |
| Sep-04-24 | Initiated | Wedbush | Outperform |
| Jul-16-24 | Initiated | Evercore ISI | Outperform |
| May-02-24 | Initiated | Robert W. Baird | Outperform |
| Mar-01-24 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Dec-20-23 | Initiated | BTIG Research | Buy |
| Dec-11-23 | Initiated | Guggenheim | Buy |
| Dec-11-23 | Initiated | Jefferies | Buy |
| May-04-20 | Initiated | Piper Sandler | Overweight |
| Mar-21-19 | Initiated | JP Morgan | Overweight |
| Sep-04-18 | Downgrade | Wells Fargo | Outperform → Market Perform |
| Apr-24-18 | Initiated | Evercore ISI | Outperform |
| Mar-14-18 | Reiterated | Needham | Buy |
View All
Spyre Therapeutics Inc Stock (SYRE) Latest News
Assessing Spyre Therapeutics (SYRE) Valuation After A Year Of Strong Shareholder Returns - Yahoo Finance
Insider Selling: Cameron Turtle Sells 15,000 Shares of Spyre Therapeutics Inc (SYRE) - GuruFocus
Scott Burrows Sells 2,500 Shares of Spyre Therapeutics (NASDAQ:SYRE) Stock - MarketBeat
Spyre Therapeutics (NASDAQ:SYRE) CEO Sells $632,850.00 in Stock - MarketBeat
Spyre Therapeutics (SYRE) CFO sells 2,500 shares under 10b5-1 plan - Stock Titan
Investment Review: Is Spyre Therapeutics Inc a top pick in the sectorPortfolio Return Report & Verified Entry Point Signals - baoquankhu1.vn
Spyre Therapeutics CEO Sells 15,000 Shares - TradingView
Support Test: Can Spyre Therapeutics Inc lead its sector in growthPortfolio Profit Report & Daily Chart Pattern Signals - baoquankhu1.vn
[144] Spyre Therapeutics, Inc. SEC Filing - Stock Titan
Aug Analyst Calls: Can Spyre Therapeutics Inc lead its sector in growth - baoquankhu1.vn
Morgan Stanley broker lists 60,000-share SYRE resale (SYRE) - Stock Titan
SYRE Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
[EFFECT] Spyre Therapeutics, Inc. SEC Filing - Stock Titan
SYRE PE Ratio & Valuation, Is SYRE Overvalued - Intellectia AI
Spyre Therapeutics, Inc. (SYRE): Investor Outlook Amid A 35% Potential Upside - DirectorsTalk Interviews
[POS AM] Spyre Therapeutics, Inc. SEC Filing - Stock Titan
Spyre Therapeutics, Inc. (NASDAQ:SYRE) Given Consensus Rating of "Buy" by Brokerages - MarketBeat
Spyre Therapeutics, Inc. targets breakthrough in inflammatory bowel disease with combination therapies - Traders Union
Spyre reports enhanced efficacy of anti-TL1A and anti-IL-23 combination - BioWorld MedTech
Assessing Spyre Therapeutics (SYRE) Valuation After A Powerful Multi‑Period Share Price Run - simplywall.st
Insider Sell: Can Spyre Therapeutics Inc maintain sales growthTrade Risk Summary & Precise Swing Trade Entry Alerts - baoquankhu1.vn
Spyre Therapeutics to Participate in Upcoming March Investor Conferences - Bitget
Bull Bear: Is Spyre Therapeutics Inc a top pick in the sector2025 Pullback Review & Weekly Top Performers Watchlists - baoquankhu1.vn
SYRESpyre Therapeutics Latest Stock News & Market Updates - Stock Titan
Spyre Therapeutics Stock Surges This Past Year as $10.5 Million Buy Lifts Stake to $78 Million - The Globe and Mail
Spyre Therapeutics Stock Surges This Past Year as $10.5 Million Buy Lifts Stake to $78 Million - The Motley Fool
Deutsche Bank Adjusts Spyre Therapeutics PT to $55 From $45, Maintains Buy Rating - marketscreener.com
Wells Fargo & Company Forecasts Strong Price Appreciation for Spyre Therapeutics (NASDAQ:SYRE) Stock - Defense World
Analysts Offer Insights on Healthcare Companies: Integer Holdings (ITGR), Spyre Therapeutics (SYRE) and Tandem Diabetes Care (TNDM) - The Globe and Mail
Gains Report: Can Spyre Therapeutics Inc. (3920) stock surprise markets with earningsMarket Sentiment Summary & Free Fast Entry Momentum Trade Alerts - mfd.ru
Spyre Therapeutics (NASDAQ:SYRE) Lowered to "Sell" Rating by Wall Street Zen - MarketBeat
Spyre Therapeutics stock hits 52-week high at 42.93 USD By Investing.com - Investing.com India
Spyre Therapeutics stock hits 52-week high at 42.93 USD - Investing.com South Africa
Spyre Therapeutics (SYRE) Buy Rating Reiterated by BTIG | SYRE S - GuruFocus
Spyre Therapeutics Stocks Surge Amid Cash Flow and Research Developments - timothysykes.com
How buybacks impact Spyre Therapeutics Inc. stock valueInflation Watch & Weekly Watchlist for Hot Stocks - mfd.ru
Spyre Therapeutics Surprises with Strong Q4 Despite Losses - StocksToTrade
Wells Fargo Raises Price Target for Spyre Therapeutics (SYRE) to $50 | SYRE Stock News - GuruFocus
Wells Fargo & Company Issues Positive Forecast for Spyre Therapeutics (NASDAQ:SYRE) Stock Price - MarketBeat
Spyre Therapeutics Stock Jumps on Pipeline Momentum - TipRanks
Spyre Therapeutics (NASDAQ:SYRE) Trading Up 6.3%Time to Buy? - MarketBeat
Spyre Therapeutics (NASDAQ:SYRE) Receives Buy Rating from BTIG Research - MarketBeat
Spyre Therapeutics (SYRE) Stock Soars Over 11% - GuruFocus
Decoding Spyre Therapeutics Inc (SYRE): A Strategic SWOT Insight - GuruFocus
Spyre Therapeutics files for mixed shelf of up to $500 million - marketscreener.com
Spyre Therapeutics Files For Mixed Shelf Of Up To $500 Million - TradingView
Spyre (SYRE) Reports Decrease in R&D Expenses and Strong Cash Po - GuruFocus
Spyre Therapeutics Q4 Loss Narrows, Cash Runway Expected Into Q2 2028 - marketscreener.com
Spyre Therapeutics (SYRE) Initiates Mixed Securities Shelf Filin - GuruFocus
Spyre Therapeutics: Q4 Earnings Snapshot - kens5.com
Earnings Flash (SYRE) Spyre Therapeutics Posts Q4 Loss $-0.70, vs. FactSet Est of Loss of $-0.71 - marketscreener.com
Spyre Therapeutics Inc Stock (SYRE) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.50%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):